567 related articles for article (PubMed ID: 26373238)
1. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
[TBL] [Abstract][Full Text] [Related]
4. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
5. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
7. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
8. Should minimal residual disease guide therapy in AML?
Paietta E
Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
[TBL] [Abstract][Full Text] [Related]
9. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
[TBL] [Abstract][Full Text] [Related]
10. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.
Feller N; van der Pol MA; van Stijn A; Weijers GW; Westra AH; Evertse BW; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2004 Aug; 18(8):1380-90. PubMed ID: 15201848
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
12. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
[TBL] [Abstract][Full Text] [Related]
13. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
14. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
[TBL] [Abstract][Full Text] [Related]
15. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
[TBL] [Abstract][Full Text] [Related]
16. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
17. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
Terwijn M; Kelder A; Snel AN; Rutten AP; Scholten WJ; Oussoren YJ; Van De Loosdrecht AA; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
Int J Lab Hematol; 2012 Aug; 34(4):432-41. PubMed ID: 22471741
[TBL] [Abstract][Full Text] [Related]
19. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]